A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

NCT07392242 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Ivosidenib
DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]